» Articles » PMID: 12943699

MAP Kinases Couple Multiple Functions of Human Progesterone Receptors: Degradation, Transcriptional Synergy, and Nuclear Association

Overview
Date 2003 Aug 29
PMID 12943699
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancers often have increased mitogen-activated protein kinase (MAPK) activity; this pathway influences breast cancer cell growth in part by targeting steroid hormone receptors. Bidirectional cross-talk between these two pathways is well documented; progestins increase the expression of type I growth factor receptors that couple to MAPK activation, and in turn, activation of p42 and p44 MAPKs increases ligand-dependent progesterone receptor (PR) transcriptional activity, and parodoxically, augments PR downregulation. Breast cancers that have become steroid hormone resistant often remain highly sensitive to growth factors. We believe that the mechanism of steroid hormone resistance is biochemically linked to the acquisition of growth factor responsiveness. Using in vitro models, we have established numerous regulatory links between signal transduction pathways elicited by peptide growth factors and PR. Of note is the role of phosphorylation of human PRs by MAPKs. Phosphorylation of PR on a key serine residue (Ser294) by MAPKs couples multiple receptor functions, including ligand-dependent PR downregulation by the ubiquitin-proteasome pathway, transcriptional synergy between progestins and growth factors, and nuclear localization of PR proteins. Linkage of these events suggests a mechanism for steroid hormone receptor "hypersensitivity" induced by growth factors. The uncoupling of these events during breast cancer progression is predicted to profoundly influence hormone responsiveness, as PR with altered stability may be driven primarily by upregulated growth factors.

Citing Articles

Association of Proteasome Activity and Pool Heterogeneity with Markers Determining the Molecular Subtypes of Breast Cancer.

Kondakova I, Sereda E, Sidenko E, Vtorushin S, Vedernikova V, Burov A Cancers (Basel). 2025; 17(1.

PMID: 39796785 PMC: 11720674. DOI: 10.3390/cancers17010159.


Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma.

Lv M, Chen P, Bai M, Huang Y, Li L, Feng Y Cancers (Basel). 2022; 14(24).

PMID: 36551694 PMC: 9776943. DOI: 10.3390/cancers14246210.


Stochastic model of ERK-mediated progesterone receptor translocation, clustering and transcriptional activity.

Marquez-Lago T, Steinberg S Sci Rep. 2022; 12(1):11791.

PMID: 35821038 PMC: 9276744. DOI: 10.1038/s41598-022-13821-x.


Membrane-Initiated Estrogen, Androgen, and Progesterone Receptor Signaling in Health and Disease.

Mauvais-Jarvis F, Lange C, Levin E Endocr Rev. 2021; 43(4):720-742.

PMID: 34791092 PMC: 9277649. DOI: 10.1210/endrev/bnab041.


Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development.

Kowalczyk W, Waliszczak G, Jach R, Dulinska-Litewka J Cancers (Basel). 2021; 13(19).

PMID: 34638264 PMC: 8507808. DOI: 10.3390/cancers13194779.